Scientific Committee takes a first look at 3-year data set

Scientific Committee takes a first look at 3-year data set

 

The DISCOVER Scientific Committee had a very productive meeting on 9–10 December 2019 in London, UK.

 

Baseline glycaemic control in the DISCOVER population

Baseline glycaemic control in the DISCOVER population

 

We are pleased to announce that an article analysing glycaemic control in patients enrolled in the DISCOVER study titled ‘Glycaemic control in patients with type 2 diabetes initiating second-line therapy: results from the global DISCOVER study programme’ has now been published in Diabetes, Obesity and Metabolism.

 

DISCOVER at EASD 2019

DISCOVER at EASD 2019

 

The DISCOVER team had a very enjoyable 55th Annual Meeting of the European Association for the Study of Diabetes (EASD), 16 – 20 September in Barcelona, Spain.

 

Treatment patterns in the global DISCOVER population

Treatment patterns in the global DISCOVER population

 

The DISCOVER team is excited to announce the publication of an article assessing first- and second-line treatments in DISCOVER patients.

 

DISCOVER STUDY AND CaReMe REGISTRY

DISCOVER STUDY AND CaReMe REGISTRY: SHAPING DIABETES TREATMENT WORLDWIDE

 

Diabetes is a large and growing global public health crisis, with a total of 415 million sufferers worldwide in 2015 – a figure that is estimated to rise to 642 million by 2040, with type 2 diabetes (T2D) accounting for the vast majority of cases.

 

DISCOVER at ADA

DISCOVER at ADA

 

Announcing DISCOVER activities at the American Diabetes Association’s 79th Scientific Sessions.

 

How inclusive are diabetes cardiovascular outcomes trials?

How inclusive are diabetes cardiovascular outcomes trials?

 

Eligibility of patients with type 2 diabetes for sodium–glucose co-transporter-2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study.

 

Global DISCOVER data recognized in journal of Cardiovascular Diabetology

Global DISCOVER data recognized in journal of Cardiovascular Diabetology

 

Prevalence of vascular complications in patients with type 2 diabetes: a prospective analysis of 15 992 patients.

 

Extent of therapeutic inertia across the world – a systematic review

How inclusive are diabetes cardiovascular outcomes trials?

 

Eligibility of patients with type 2 diabetes for sodium–glucose co-transporter-2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study

 

Extent of therapeutic inertia across the world – a systematic review

Health-related quality of life

 

Professor Nicolucci presented interesting data on the health-related quality of life in DISCOVER patients.

 

Extent of therapeutic inertia across the world – a systematic review

DISCOVER study presented at ICPE 2018

 

Diversity of sites, physicians and patients in the DISCOVER study presented at ICPE 2018.

 

DISCOVER at EASD 2018

Presenting DISCOVER activities at EASD 2018 in Berlin, Germany.

 

The DISCOVER study

 

DISCOVER is a global, prospective, observational study of patients with type 2 diabetes starting second-line glucose-lowering therapy. The study enrolled nearly 16 000 patients in 38 countries across six continents, who were followed up for 3 years. The study was completed in 2019 and provides a comprehensive and contemporary picture of treatment patterns and outcomes in patients with type 2 diabetes worldwide.

 

Type 2 diabetes and real world evidence

 

The DISCOVER study is designed to generate real world evidence (RWE) about people living with type 2 diabetes across the globe. RWE is key to understanding more about type 2 diabetes and how it is managed in day-to-day clinical practice, and therefore contributes to improved disease management.

 

DISCOVER publications

 

The DISCOVER study is providing unprecedented global insights into the treatment of type 2 diabetes. The DISCOVER Scientific Committee is continuing to publish abstracts, posters, oral presentations and journal articles about the DISCOVER study results at the global, regional and local levels.

 

The DISCOVER study

The DISCOVER study

 

DISCOVER is a global, prospective, observational study of patients with type 2 diabetes starting second-line glucose-lowering therapy. The study enrolled nearly 16 000 patients in 38 countries across six continents, who were followed up for 3 years. The study was completed in 2019 and provides a comprehensive and contemporary picture of treatment patterns and outcomes in patients with type 2 diabetes worldwide.

 
 

Type2 diabetes and real world evidence

Type 2 diabetes and real world evidence

The DISCOVER study is designed to generate real world evidence (RWE) about people living with type 2 diabetes across the globe. RWE is key to understanding more about type 2 diabetes and how it is managed in day-to-day clinical practice, and therefore contributes to improved disease management.

 

DISCOVER publications

DISCOVER publications

 

The DISCOVER study is providing unprecedented global insights into the treatment of type 2 diabetes. The DISCOVER Scientific Committee is continuing to publish abstracts, posters, oral presentations and journal articles about the DISCOVER study results at the global, regional and local levels.